Treventis Corporation is dedicated to treating and preventing protein misfolding diseases. They utilize a proprietary, patent-pending discovery engine, Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets.